Taking the medication mavacamten for HCM can reduce obstruction in your heart. Learn about its benefits, risks, and side ...

The number of patients diagnosed with cardiomyopathy has increased substantially over the past two decades. This is the ...

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...

Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...

Please provide your email address to receive an email when new articles are posted on . Genetic risk for dilated cardiomyopathy was tied to elevated risk for secondary cardiomyopathies related to ...

Patients reveal persistent gaps in genetic testing, diagnosis, and clinical trial access—and implications for advancing ...

The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...

Cardiomyopathy is a disease of the heart muscles which may cause them to become enlarged and inflamed. Inflamed muscles become stretched, weak, less efficient at pumping blood and less able to ...

FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial in hereditary transthyretin amyloidosis with polyneuropathy. The decision allows the late stage study of Intellia's ...